Skip to main content

Antiobesity Effect of Lacticaseibacillus paracasei LM-141 on High-Fat Diet-Induced Rats through Alleviation of Inflammation and Insulin Resistance

  • 2023-04-18
  • Evidence-Based Complementary and Alternative Medicine 2023
    • Ching-Shuang Wu
    • Chih-Chieh Lin
    • Feng-Ching Hsieh
    • Tai-Yun Wu
    • Ai-Hui Fang

Abstract

In this study, we set out to evaluate the antiobesity activities of our newly isolated Lacticaseibacillus paracasei LM-141 (LPLM141) using a high-fat diet (HFD)-fed rat model. Male Sprague-Dawley rats were fed with a HFD with or without low-dosage (2 × 107 CFU/day per rat) or high-dosage (2 × 109 CFU/day per rat) LPLM141 for 14 weeks. The results showed that administration of LPLM141 significantly decreased body weight gain, liver weight, adipose tissue weight, and epididymal white adipocyte size increased by HFD feeding. The abnormal serum lipid profile induced by HFD feeding was normalized by administration of LPLM141. The enhanced chronic low-grade inflammation in HFD-fed rats was reduced by LPLM141 supplementation, as reflected by decreased serum lipopolysaccharide (LPS) and monocyte chemoattractant protein-1 (MCP-1) levels, reduced macrophage infiltration in adipose tissue, and increased serum adiponectin concentration. In addition, the elevations of proinflammatory cytokine genes and suppression of PPAR-γ mRNA in adipose tissues of rats fed with a HFD were markedly reversed by LPLM141 administration. Oral administration of LPLM141 induced browning of epididymal white adipose tissue (eWAT) and activation of interscapular brown adipose tissue (iBAT) in rats fed with HFD. Consumption of LPLM141 exhibited a significant amelioration in insulin resistance, which were mechanistically caused by downregulation of the serum leptin level and upregulation of hepatic IRS-1 and p-Akt protein expressions, in HFD treated rats. LPLM141 consumption significantly decreased hepatic lipogenic gene expressions and preserved liver function stimulated by HFD treatment. Administration of LPLM141 obviously mitigated hepatic steatosis observed in HFD feeding rats. Our current findings shed light on LPLM141 supplementation that exhibited an antiobesity effect in HFD-fed rats by alleviating inflammation and insulin resistance, which further highlighted the potential of utilizing LPLM141 as a preventive/therapeutic probiotic agent for obesity.

Research Insights

SupplementHealth OutcomeEffect TypeEffect Size
Lacticaseibacillus paracasei Lpc-37Improved Insulin SensitivityBeneficial
Large
Lacticaseibacillus paracasei Lpc-37Improved Lipid ProfileBeneficial
Large
Lacticaseibacillus paracasei Lpc-37Induction of Browning of White Adipose TissueBeneficial
Moderate
Lacticaseibacillus paracasei Lpc-37Preserved Liver FunctionBeneficial
Large
Lacticaseibacillus paracasei Lpc-37Reduced Hepatic SteatosisBeneficial
Large
Lacticaseibacillus paracasei Lpc-37Reduced Inflammation LevelsBeneficial
Large
Lacticaseibacillus paracasei Lpc-37Reduced Weight GainBeneficial
Large

Pillser helps you make informed health decisions by providing comprehensive, unbiased information about supplements. This includes detailed research on supplement ingredients, their benefits, potential risks, and their overall efficacy. You can contribute by sharing your feedback and suggestions.

Send us an email at support@pillser.com.